Shares of STADA Arzneimittel AG (ETR:SAZ) have earned a consensus recommendation of “Sell” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is €69.07 ($81.26).

SAZ has been the subject of several research analyst reports. S&P Global set a €66.25 ($77.94) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Tuesday, July 11th. Independent Research GmbH set a €66.25 ($77.94) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Tuesday, July 11th. Commerzbank Ag set a €66.00 ($77.65) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Monday, July 10th. Warburg Research set a €60.00 ($70.59) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Wednesday, July 5th. Finally, Kepler Capital Markets set a €66.00 ($77.65) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Tuesday, July 4th.

STADA Arzneimittel AG (ETR SAZ) opened at 82.20 on Friday. The company has a 50 day moving average price of €81.27 and a 200-day moving average price of €69.29. The firm has a market capitalization of €5.12 billion and a price-to-earnings ratio of 54.33. STADA Arzneimittel AG has a 1-year low of €41.40 and a 1-year high of €84.20.

COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/20/stada-arzneimittel-ag-saz-receives-average-recommendation-of-sell-from-analysts.html.

About STADA Arzneimittel AG

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.